Lysis in Medical Technology
Navigation Links
Lysis in Medical Technology
... malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) ... allopurinol alone (p=0.06).
Tumor lysis syndrome is a potentially life-threatening ... (p=0.06). Among patients at high risk for tumor lysis syndrome, the PUA response rate was 89% with ...
... IgE target antigens, all showed high potency as demonstrated by redirected lysis of respective target cells at half maximal concentrations below 1 ng/ml ... how to recruit T cells for a very selective and highly effective lysis of target cells. Proof of concept has been established for the BiTE ...
... for the treatment of patients with KRAS- and BRAF-mutated colorectal cancer is now possible." (1)Lutterbuese, R. et al. Highly efficient lysis of KRAS- and BRAF-mutated human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab ...
... and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are ...
... and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are ...
... eight weeks from start of treatment) occurred in four patients (7 percent) in the DR group and two patients (3 percent) in the BFR group. Tumor lysis syndrome was also reported following treatment with ofatumumab. Common adverse reactions (greater than or equal to 10%) were pyrexia, cough, ...
... and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are ...
... a phase 2 study investigating the activity of adecatumumab in colon cancer patients with completely resected liver metastases." (1) ADCC-mediated lysis of KRAS-mutated Colon Cancer Cells by Anti-EpCAM Antibody Adecatumumab. D. Ruttinger et al. 23rd annual meeting of iSBTc, San Diego Nov. 1st (2008; ...
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune ...
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune ...
... Act of 1995. These statements include the finalization of paperwork with the NIH and work commencement; the reported effectiveness of PCT in cell lysis and isolation of subcellular molecular complexes, including organelles; the speed, reproducibility, quality, and simplicity of sample preparation ...
... of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and infusion-related reactions. A scientific report of the safety and efficacy findings from this study was published earlier this year in the ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
... and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... cells to which the original hESC cell line was exposed in its initial derivation. Expression of such non-human antigens would typically lead to lysis by antibodies present in the sera of normal individuals. In the studies, GRNOPC1 cells were tested for susceptibility to both immune effector cells ...
... 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transient reduction ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... IgE target antigens, all showed high potency as demonstrated by redirected lysis of respective target cells at half maximal concentrations below 1 ng/ml ... how to recruit T cells for a very selective and highly effective lysis of target cells. Proof of concept has been established for the BiTE ...
... for the treatment of patients with KRAS- and BRAF-mutated colorectal cancer is now possible." (1)Lutterbuese, R. et al. Highly efficient lysis of KRAS- and BRAF-mutated human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab ...
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune ...... and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are ...
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
... Superiority of Rasuburicase vs. Allopurinol on serum uric acid control in adult patients with hematologic malignancies at risk of developing Tumor lysis Syndrome Multiple Myeloma Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II study ...... and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are ...
... eight weeks from start of treatment) occurred in four patients (7 percent) in the DR group and two patients (3 percent) in the BFR group. Tumor lysis syndrome was also reported following treatment with ofatumumab. Common adverse reactions (greater than or equal to 10%) were pyrexia, cough, ...
... and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are ...
... a phase 2 study investigating the activity of adecatumumab in colon cancer patients with completely resected liver metastases." (1) ADCC-mediated lysis of KRAS-mutated Colon Cancer Cells by Anti-EpCAM Antibody Adecatumumab. D. Ruttinger et al. 23rd annual meeting of iSBTc, San Diego Nov. 1st (2008; ...
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune ...
InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International
... as a cell culture ingredient in mammalian cell culture media. (see http://www.Lacromin.com ) -- Lysobac -- Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher protein yield compared with mechanical cell ...... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune ...
... Act of 1995. These statements include the finalization of paperwork with the NIH and work commencement; the reported effectiveness of PCT in cell lysis and isolation of subcellular molecular complexes, including organelles; the speed, reproducibility, quality, and simplicity of sample preparation ...
... of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune ...... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...... group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and infusion-related reactions. A scientific report of the safety and efficacy findings from this study was published earlier this year in the ...
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
... of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response ...... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
... and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
... recovered fully. Two cases of grade 3 thrombocytopaenia were reported. In the 2mg/kg/infusion group, one patient was diagnosed to have Tumour lysis Syndrome following 2 infusions of drug. - ENDS - Annabel Entress Account ...... cells to which the original hESC cell line was exposed in its initial derivation. Expression of such non-human antigens would typically lead to lysis by antibodies present in the sera of normal individuals. In the studies, GRNOPC1 cells were tested for susceptibility to both immune effector cells ...
... 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transient reduction ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
... hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor ...
Other ContentsalkalinealkalinealkalinealkalinealkalinealkalinealkalinealkalinealkalineagentsagentsagentsagentsagentsagentsagentsagentsagentsalkylatingalkylatingallantoisallostericallostericallostericmalemalemalemalemalemalemalemalemaleOther TagsStandardStandardStandardStandardStandardRibonucleicMastercyclerMastercyclerBakerCorningCorningRabbitRabbit
(Date:12/16/2009)... IgeaCare Solutions Inc. is pleased to ... healthcare communications company previously operating as IgeaCare Systems ... move forward under new leadership and funding. ,, ... to the position of Chief Executive Officer. Under ... providing a superior servicing and support model; fast ...
(Date:12/16/2009)... European Union (EU) member states are spending ... increasingly subjected to unauthorised immigration and illegal ... security and IT-based systems will boost the ... ) ,, New analysis from Frost & ... Market Assessment - European Union , finds ...
(Date:12/15/2009)... British Society for Research on Ageing (BSRA) to enter ... for an initial period of three years. The ... editorial board and will acquire articles for one ... and provide society members with free electronic access to ... Biogerontology offers a platform for research which aims ...
Breaking Biology News(10 mins):IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators 28ACATA 29 47495 1Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators 28ACATA 29 47495 2Edward Diehl Receives Outstanding Achievement Award From the American College of Addiction Treatment Administrators 28ACATA 29 47495 3Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 47493 1Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 47493 2Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 47493 3Availity Teams with Thomson Reuters to Integrate Treatment Cost Calculator 47491 1Availity Teams with Thomson Reuters to Integrate Treatment Cost Calculator 47491 2(Date:12/17/2009)... hired Deirdre Byrne to lead the firm’s Interim Leadership division as ... experience in healthcare consulting, Byrne will assume her duties at B. ... ... 17, 2009 -- B. E. Smith recently hired Deirdre ... president. A seasoned executive with nearly 20 years of experience in ...
(Date:12/17/2009)... 17 Motionsoft, Inc. announced today that ... Industry (PCI) Data Security Standards (DSS) certification, making ... vendors in the health and wellness space that ... Standard is the result of a collaborative effort ... (Visa International, MasterCard Worldwide, American Express, Discover Financial ...
(Date:12/17/2009)... PHILADELPHIA, Dec. 17 The recently opened ... already out in the community in full force this ... Run on December 13th, benefiting the Arthritis Foundation, a ... of arthritis. The event boasted 1,500 attendees, spotlighting LSI,s ... Run is a renowned, national fundraiser and a festive ...
(Date:12/17/2009)... S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null ... cancer. The results regarding the association between GSTM1 and ... CRC were contradictory. However, the majority of previous reports ... association of the GSTM1/GSTT1 null genotype with the risk ... studies with larger numbers of samples. , A ...
(Date:12/17/2009)... 2009) Researchers from the La Jolla Institute for Allergy ... world,s most dangerous infectious diseases tuberculosis, malaria and ... set of projects seeking to make new inroads toward ... received four project awards totaling $18.8 million from the ... of the National Institutes of Health, to fund the ...
Breaking Medicine News(10 mins):Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Motionsoft Completes PCI Compliance Certification 2Health News:Laser Spine Institute (LSI) Supports Jingle Bell Run 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5[0] Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services[0] Motionsoft Completes PCI Compliance Certification[0] Laser Spine Institute (LSI) Supports Jingle Bell Run[0] Does Glutathione-S-transferase associate with gastrointestinal cancer in Korean population?[0] NIH awards La Jolla Institute $18.8 million for major infectious disease study
StandardRibonucleicGenomONEHistologyMastercyclerOrfmerAAIBiotechEnolaseUNOsphereBakerCorningBlasticidinRabbitGlutathione
Other Tagswebsite 2website 3website 4website 5website 6website 7website 8website 9infrastructure 2infrastructure 3infrastructure 4infrastructure 5infrastructure 6infrastructure 7infrastructure 8infrastructure 9substantial 2substantial 3substantial 4substantial 5substantial 6substantial 7substantial 8microbiology 2microbiology 3microbiology 4microbiology 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |